T1	control 49 67	fulvestrant 250 mg
T2	intervention 73 91	fulvestrant 500 mg
T4	outcome 1570 1573	QOL
T5	outcome 1336 1340	DoCB
T6	outcome 1345 1347	OS
T3	eligibility 283 416	postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior endocrine therapy
T7	outcome-Measure 760 791	progression-free survival (PFS)
T9	outcome 964 967	PFS
T10	intervention-participants 1021 1024	362
T11	control-participants 1043 1046	374
T14	outcome 1165 1188	Objective response rate
T15	iv-bin-percent 1236 1240	9.1%
T16	cv-bin-percent 1243 1248	10.2%
T17	outcome 1265 1268	CBR
T18	iv-bin-percent 1273 1278	45.6%
T19	cv-bin-percent 1306 1311	39.6%
T20	iv-cont-median 1353 1357	16.6
T21	cv-cont-median 1362 1373	25.1 months
T22	outcome 1419 1423	DoCB
T23	outcome 1428 1430	OS
T24	cv-cont-median 1436 1440	13.9
T25	cv-cont-median 1445 1456	22.8 months
T12	outcome 1516 1530	well tolerated
T13	outcome 1554 1568	adverse events
T8	outcome-Measure 823 846	objective response rate
T26	outcome-Measure 848 875	clinical benefit rate (CBR)
T27	outcome-Measure 877 912	duration of clinical benefit (DoCB)
T28	outcome-Measure 914 935	overall survival (OS)
T29	outcome-Measure 941 962	quality of life (QOL)
